Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI

Blood

Volumn 113, Issue 4, 2009, Pages 953-962

  Li, Nainong ^a,c   Chen, Ying ^a   He, Wei ^a   Yi, Tangsheng ^a   Zhao, Dongchang ^a   Zhang, Chunyan ^a   Lin, Chia Lei ^a   Todorov, Ivan ^a   Kandeel, Fouad ^a   Forman, Stephen ^b   Zeng, Defu ^b  

^a Department of Diabetes and Endocrinology ^*

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR9; HOMING RECEPTOR; MONOCLONAL ANTIBODY CD3; ALPHA E INTEGRINS; ALPHA INTEGRIN; ANTIBODY; CD3 ANTIGEN; CHEMOKINE RECEPTOR; LEUKOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOST; HOST CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MESENTERY LYMPH NODE; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TARGET ORGAN; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; ANIMAL; BLOOD DONOR; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; CYTOLOGY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; PATHOLOGY; SECRETION; UPREGULATION;

ANIMALS; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD3; BLOOD DONORS; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINES; DENDRITIC CELLS; DOWN-REGULATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTEGRIN ALPHA CHAINS; LEUKEMIA; MICE; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UP-REGULATION; WHOLE-BODY IRRADIATION;

EID: 59649086980     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-165522     Document Type: Article

References (60)

1. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigenpresenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med. 2005; 11:1244-1249.
2. Chakraverty R, Sykes M. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood. 2007; 110:9-17.
3. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340-352.
4. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-170.
5. Ferrara J, Antin.J. The pathophysiology of graftvs.- host disease. In: Blume KG, Forman SJ, Appelbaum FR, eds. Thomas' hematopoietic cell transplantation. Malden, MA: Blackwell Publishing Ltd; 2004:353-368.
6. Panoskaltsis-Mortari A, Price A, Hermanson JR, et al. In vivo imaging of graft-versus-host-disease in mice. Blood. 2004;103:3590-3598.
7. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T cell subsets. Blood. 2005;106:1113-1122.
8. Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest. 2003;111:659-669.
9. Zhang C, Lou J, Li N, et al. Donor CD8-T cells mediate graft-versus-leukemia activity without clinical signs of graft-versus-host disease in recipients conditioned with anti-CD3 monoclonal antibody. J Immunol. 2007;178:838-850.
10. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
11. Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172: 7393-7398.
12. Sackstein R. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006;12:2-8.
13. Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Marquez G, Agace W. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med. 2003;198: 963-969.
14. Mora JR, Cheng G, Picarella D, Briskin M, Buchanan N, von Andrian UH. Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J Exp Med. 2005;201:303-316.
15. Iwata M, Hirakiyama A, Eshima Y, Kagechika H, Kato C, Song SY. Retinoic acid imprints gut-homing specificity on T cells. Immunity. 2004;21:527-538.
16. Tietz W, Allemand Y, Borges E, et al. CD4-T cells migrate into inflamed skin only if they express ligands for E- and P-selectin. J Immunol. 1998;161:963-970.
17. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med. 2001;194:1541-1547.
18. Sigmundsdottir H, Pan J, Debes GF, et al. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol. 2007;8:285-293.
19. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, Serody JS. Leukocyte migration and graft-versushost disease. Blood. 2005;105:4191-4199.
20. Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, et al. Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning. J Immunol. 2004;173:845-854.
21. Duffner U, Lu B, Hildebrandt GC, et al. Role of CXCR3-induced donor T cell migration in acute GVHD. Exp Hematol. 2003;31:897-902.
22. Hildebrandt GC, Corrion LA, Olkiewicz KM, et al. Blockade of CXCR3 receptor:ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome. J Immunol. 2004;173:2050-2059.
23. Varona R, Cadenas V, Gomez L, Martinez AC, Marquez G. CCR6 regulates CD4-T cell-mediated acute graft-versus-host disease responses. Blood. 2005;106:18-26.
24. Terwey TH, Kim TD, Kochman AA, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood. 2005;106:3322-3330.
25. Jaksch M, Remberger M, Mattsson J. Increased gene expression of chemokine receptors is correlated with acute graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:280-287.
26. Chakraverty R, Cote D, Buchli J, et al. An inflammatory checkpoint regulates recruitment of graftversus- host reactive T cells to peripheral tissues. J Exp Med. 2006;203:2021-2031.
27. Johansson-Lindbom B, Svensson M, Pabst O, et al. Functional specialization of gut CD103-dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med. 2005;202:1063-1073.
28. Ohl L, Mohaupt M, Czeloth N, et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity. 2004; 21:279-288.
29. Kim TD, Terwey TH, Zakrzewski JL, et al. Organderived dendritic cells have differential effects on alloreactive T cells. Blood. 2008;111:2929-2940.
30. Beilhack A, Schulz S, Baker J, et al. Prevention of acute graft-versus-host disease by blocking T cell entry to secondary lymphoid organs. Blood. 2008; 111:2919-2928.
31. Zhang Y, Shlomchik WD, Joe G, et al. APCs in the liver and spleen recruit activated allogeneic CD8-T cells to elicit hepatic graft-versus-host disease. J Immunol. 2002;169:7111-7118.
32. Mapara MY, Leng C, Kim YM, et al. Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. Biol Blood Marrow Transplant. 2006; 12:623-634.
33. Decalf J, Fernandes S, Longman R, et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med. 2007; 204:2423-2437.
34. Turnbull EL, Yrlid U, Jenkins CD, Macpherson GG. Intestinal dendritic cell subsets: differential effects of systemic TLR4 stimulation on migratory fate and activation in vivo. J Immunol. 2005;174: 1374-1384.
35. Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107:1581-1589.
36. Muraille E, Andris F, Pajak B, et al. Downregulation of antigen-presenting cell functions after administration of mitogenic anti-CD3 monoclonal antibodies in mice. Blood. 1999;94:4347-4357.
37. Yi T, Zhao D, Lin CL, et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood. 2008;112:2101-2110.
38. Drakes ML, Czinn SJ, Blanchard TG. Isolation and purification of colon lamina propria dendritic cells from mice with colitis. Cytotechnology. 2004; 46:151-161.
39. Zeng D, Hoffmann P, Lan F, Huie P, Higgins J, Strober S. Unique patterns of surface receptors, cytokine secretion, and immune functions distinguish T cells in the bone marrow from those in the periphery: impact on allogeneic bone marrow transplantation. Blood. 2002;99:1449-1457.
40. Zhao D, Zhang C, Yi T, et al. In vivo-activated CD103-CD4-regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood. 2008;112:2129-2138.
41. Yang F, Huang X, Yi T, Yen Y, Moore DD, Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007;67:863-867.
42. Murai M, Yoneyama H, Harada A, et al. Active participation of CCR5(-)CD8(-) T lymphocytes in the pathogenesis of liver injury in graft-versushost disease. J Clin Invest. 1999;104:49-57.
43. Beaty SR, Rose CE Jr, Sung SS. Diverse and potent chemokine production by lung CD11bhigh dendritic cells in homeostasis and in allergic lung inflammation. J Immunol. 2007;178:1882-1895.
44. Stenstad H, Svensson M, Cucak H, Kotarsky K, Agace WW. Differential homing mechanisms regulate regionalized effector CD8alphabeta-T cell accumulation within the small intestine. Proc Natl Acad Sci U S A. 2007;104:10122-10127.
45. Hieshima K, Kawasaki Y, Hanamoto H, et al. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J Immunol. 2004;173:3668-3675.
46. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88: 3230-3239.
47. Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, Shlomchik WD. Target antigens determine graft-versus-host disease phenotype. J Immunol. 2004;173:5467-5475.
48. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol. 2003;171:1272-1277.
49. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol. 2002;283:R7-28.
50. Mucida D, Park Y, Kim G, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317:256-260.
51. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, et al. A functionally specialized population of mucosal CD103-DCs induces Foxp3-regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757-1764.
52. Li N, Zhao D, Kirschbaum M, et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci U S A. 2008;105:4796-4801.
53. Perruche S, Zhang P, Liu Y, Saas P, Bluestone JA, Chen W. CD3-specific antibody-induced immune tolerance involves transforming growth factor- beta from phagocytes digesting apoptotic T cells. Nat Med. 2008;14:528-535.
54. Zeng D, Lan F, Hoffmann P, Strober S. Suppression of graft-versus-host disease by naturally occurring regulatory T cells. Transplantation. 2004; 77:S9-S11.
55. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
56. Giralt S. Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years? Hematology Am Soc Hematol Educ Program 2005:384-389.
57. Johnson BD, McCabe C, Hanke CA, Truitt RL. Use of anti-CD3 epsilon F(ab-)2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J Immunol. 1995;154:5542-5554.
58. Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation. 2006;81:953-965.
59. Blazar BR, Jenkins MK, Taylor PA, et al. Anti-CD3 epsilon F(ab-)2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen. J Immunol. 1997;159:5821-5833.
60. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol. 2007;7:622-632.